Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Beasley

Showing results (61-70 of 443) with videos related to

Pageof 45
Sort By:
The Lancet. Respiratory Medicine|February 19, 2020
Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practiceRichard Beasley, James Harper, Matthew Masoli
American Journal of Respiratory and Critical Care Medicine|February 18, 2021
Asthma and COVID-19: Preconceptions about PredispositionRichard Beasley, Thomas Hills, Nethmi Kearns
The Lancet. Respiratory Medicine|August 20, 2021
Charting a course for the management of long COVIDRichard Beasley, Nethmi Kearns, Tom Hills
The New Zealand Medical Journal|April 5, 2005
SIT (seated immobility thromboembolism) syndrome: a 21st century lifestyle hazardRichard Beasley, Patricia Heuser, Nigel Raymond
The Journal of Allergy and Clinical Immunology|February 10, 2004
Increasing compliance with inhaled corticosteroids through the use of combination therapySean Holt, Matthew Masoli, Richard Beasley
Current Opinion in Pulmonary Medicine|October 20, 2017
Treatable traits of chronic airways diseaseJames Fingleton, Jo Hardy, Richard Beasley
American Journal of Respiratory and Critical Care Medicine|September 8, 2009
Potential risks of using LABAs with ICS therapyRichard Beasley, Meme Wijesinghe, Mark Weatherall
Current Opinion in Allergy and Clinical Immunology|October 6, 2012
The β-2 agonist debate: is there still a problem?Mitesh Patel, Philippa Shirtcliffe, Richard Beasley
Clinical Immunotherapeutics|April 1, 2020
An Approach to the Management of High Risk Asthmatic PatientsJon Miles, Penny Fitzharris, Richard Beasley
Thorax|January 21, 2011
Towards individualised treatment in COPDJames Fingleton, Mark Weatherall, Richard Beasley
Pageof 45

Showing results (61-70 of 443) with videos related to

Sort By:
Pageof 45
The Lancet. Respiratory Medicine|February 19, 2020
Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practiceRichard Beasley, James Harper, Matthew Masoli
American Journal of Respiratory and Critical Care Medicine|February 18, 2021
Asthma and COVID-19: Preconceptions about PredispositionRichard Beasley, Thomas Hills, Nethmi Kearns
The Lancet. Respiratory Medicine|August 20, 2021
Charting a course for the management of long COVIDRichard Beasley, Nethmi Kearns, Tom Hills
The New Zealand Medical Journal|April 5, 2005
SIT (seated immobility thromboembolism) syndrome: a 21st century lifestyle hazardRichard Beasley, Patricia Heuser, Nigel Raymond
The Journal of Allergy and Clinical Immunology|February 10, 2004
Increasing compliance with inhaled corticosteroids through the use of combination therapySean Holt, Matthew Masoli, Richard Beasley
Current Opinion in Pulmonary Medicine|October 20, 2017
Treatable traits of chronic airways diseaseJames Fingleton, Jo Hardy, Richard Beasley
American Journal of Respiratory and Critical Care Medicine|September 8, 2009
Potential risks of using LABAs with ICS therapyRichard Beasley, Meme Wijesinghe, Mark Weatherall
Current Opinion in Allergy and Clinical Immunology|October 6, 2012
The β-2 agonist debate: is there still a problem?Mitesh Patel, Philippa Shirtcliffe, Richard Beasley
Clinical Immunotherapeutics|April 1, 2020
An Approach to the Management of High Risk Asthmatic PatientsJon Miles, Penny Fitzharris, Richard Beasley
Thorax|January 21, 2011
Towards individualised treatment in COPDJames Fingleton, Mark Weatherall, Richard Beasley
Pageof 45